Sonora Quest and Laboratory Sciences of Arizona Announce Jennifer Erickson as CEO-Elect
Rhea-AI Summary
Sonora Quest Laboratories (NYSE:DGX) named Jennifer Erickson as Chief Executive Officer‑Elect, succeeding longtime CEO David Dexter, who will retire effective March 31, 2026. Dexter will work with Erickson starting Feb. 2, 2026 to complete a planned transition. Dexter led the company for more than 26 years, overseeing growth to a market‑share leadership position in Arizona and operations performing more than 100 million diagnostic tests per year. Erickson brings over 20 years of health‑care leadership and previously served as Sonora Quest CFO (1999–2004).
Positive
- Planned transition window from Feb. 2 to Mar. 31, 2026
- Jennifer Erickson brings >20 years of health‑care leadership experience
- Internal successor with prior Sonora Quest CFO role (1999–2004)
- Continuity emphasized: CEO mentor relationship spans 26 years
Negative
- Departure of CEO David Dexter after >26 years of leadership
- Potential short‑term execution risk during leadership handover through March 31, 2026
News Market Reaction – DGX
In the Jan 15 session, DGX gained 1.87%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Earnings timing | Neutral | -0.2% | Announced date and call details for Q4 and full-year 2025 results. |
| Jan 06 | Clinical data update | Positive | +4.0% | Haystack MRD® data to be presented at 2026 ASCO GI symposium. |
| Jan 05 | Joint venture deal | Positive | -0.2% | Completed Diagnostic Lab of Michigan JV with Corewell Health. |
| Dec 19 | Conference appearance | Neutral | -0.1% | Planned presentation at the 44th J.P. Morgan Healthcare Conference. |
| Dec 09 | Clinical collaboration | Positive | -1.2% | Haystack MRD collaboration for Phase II MRD-PORT lung cancer trial. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent DGX news shows mixed reactions: positive scientific and partnership updates sometimes align with gains, but there are also instances where constructive news coincided with modest declines.
Over the past months, Quest Diagnostics has highlighted several strategic and scientific developments. A Michigan joint venture expanded lab access, and multiple Haystack MRD® updates underscored its oncology focus, including ASCO GI data and a lung cancer trial collaboration noted in 2025. Investor communications have included J.P. Morgan conference materials and upcoming Q4/FY 2025 earnings timing. Against this backdrop, today’s leadership-related announcement at a key affiliate fits into a narrative of ongoing network and capability expansion.
Key Terms
clinical laboratory testing medical
diagnostic tests medical
direct-access testing medical
COVID-19 diagnostic testing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Jennifer Erickson succeeds longtime CEO David Dexter following more than 26 years of service
Dexter joined Sonora Quest and LSA as president and CEO in 1999, where under his leadership, the company has grown tremendously, serving as the market share leader in clinical laboratory testing in
Starting on Feb. 2, Dexter will work closely with Erickson to ensure a smooth transition over the coming months. Dexter will be retiring as of March 31.
"As I've reflected on my years as CEO, I have a blend of emotions — gratitude, pride, and nostalgia," said Dexter. "My fondest memories aren't of milestones reached or metrics made, but of the people with whom I've worked, the resilience during challenges and tough times, and the creativity and innovation that's been brought to every opportunity."
Dexter has led Sonora Quest and LSA through many major milestones, including the development of its direct-access testing platform, My Lab ReQuest™, in 2015, and the launch of Operation Catapult to expand Sonora Quest's COVID-19 diagnostic testing capacity in 2020. He also supported many ongoing collaborations with community partners, such as the American Cancer Society, Aunt Rita's Foundation, and CommunityCares, helping broaden the reach of diagnostic testing for patients statewide. Together, these efforts strengthened access, innovation, and resilience across
Erickson will continue Dexter's legacy of growth and innovation. As an executive with a proven track-record in driving performance, culture and profitability, Erickson will continue to focus on advancing patient-centered diagnostics, strengthening partnerships and fostering a culture of collaboration and accountability.
Dexter noted, "I personally have mentored Jennifer for 26 years, and have had the privilege of working alongside her during that time. I know that she is an excellent fit for the role and am very confident that she will carry on the spirit of a fearless leader."
Erickson brings more than 20 years of experience leading high-performance health care and consumer services companies; most recently as Chief Financial Officer and Chief Operating Officer of Clin-Path Associates/Pathology Specialists of
"Returning to lead the company that gave me such a strong foundation in health care leadership, now in the role once held by my mentor, is both an honor and great responsibility," said Erickson. "This is a full-circle moment that underscores the lasting impact of strong leadership and intentional mentorship. I look forward to building on a legacy defined by forward thinking, meaningful relationships, and care for the people we serve."
For more information about Sonora Quest, and LSA, visit www.SonoraQuest.com.
About Sonora Quest Laboratories
Sonora Quest Laboratories, a subsidiary of Laboratory Sciences of
MEDIA CONTACT
LAVIDGE
SQL@lavidge.com
480.998.2600
View original content to download multimedia:https://www.prnewswire.com/news-releases/sonora-quest-and-laboratory-sciences-of-arizona-announce-jennifer-erickson-as-ceo-elect-302662219.html
SOURCE Sonora Quest Laboratories